Company Announcements
Director/PDMR Shareholding
Related Companies
GlaxoSmithKline plc (the 'Company')
Transaction notification
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr R G Connor |
||||
|
b) |
Position/status |
President, Global Manufacturing & Supply |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr R Connor will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-09-23 |
||||
|
f) |
Place of the transaction
|
n/a
|
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr S A Hussain |
||||
|
b) |
Position/status |
President, Global Pharmaceuticals |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Hussain will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-09-23 |
||||
|
f) |
Place of the transaction
|
n/a
|
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Mr D S Redfern |
||||
|
b) |
Position/status |
Chief Strategy Officer |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-09-23 |
||||
|
f) |
Place of the transaction
|
n/a
|
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Ms C Thomas |
||||
|
b) |
Position/status |
SVP, Human Resources |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £237,076.13 less applicable tax withholding in respect of 14,376.963 notional Ordinary Shares.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-09-23 |
||||
|
f) |
Place of the transaction
|
n/a
|
||||
|
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
|
a) |
Name |
Dr P J T Vallance |
||||
|
b) |
Position/status |
President, Pharmaceuticals Research & Development |
||||
|
c) |
Initial notification/ amendment |
Initial notification |
||||
|
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a) |
Name |
GlaxoSmithKline plc |
||||
|
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
|
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
|
a) |
Description of the financial instrument |
Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
|
b) |
Nature of the transaction |
Following the vesting on 23 September 2016 of 50% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Vallance will receive a cash payment of £296,345.16 less applicable tax withholding in respect of 17,971.204 notional Ordinary Shares.
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
Aggregated volume Price |
n/a (single transaction)
|
||||
|
e) |
Date of the transaction |
2016-09-23 |
||||
|
f) |
Place of the transaction
|
n/a
|
||||
This information is provided by RNS
You are here: news > regulatory news
10 Lower Thames St,
London EC3R 6EN